Mesoblast (NASDAQ:MESO) Shares Gap Up – Should You Buy?

Mesoblast Limited (NASDAQ:MESO) gapped up before the market opened on Tuesday . The stock had previously closed at $12.10, but opened at $12.70. Mesoblast shares last traded at $12.57, with a volume of 24,916 shares.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Jefferies Financial Group raised shares of Mesoblast from a “hold” rating to a “buy” rating in a report on Thursday, August 29th. StockNews.com cut shares of Mesoblast from a “hold” rating to a “sell” rating in a research note on Wednesday, September 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a report on Thursday, August 29th. Finally, Maxim Group raised Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Tuesday, September 24th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $11.50.

Mesoblast Trading Down 2.1 %

The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. The business has a fifty day simple moving average of $10.24 and a two-hundred day simple moving average of $8.17.

Hedge Funds Weigh In On Mesoblast

Large investors have recently made changes to their positions in the business. Jane Street Group LLC increased its stake in Mesoblast by 46.4% during the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after purchasing an additional 26,959 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Mesoblast during the 2nd quarter valued at $562,000. Lazari Capital Management Inc. grew its position in Mesoblast by 6.6% during the second quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company’s stock valued at $364,000 after buying an additional 3,300 shares during the period. XY Capital Ltd bought a new stake in Mesoblast during the 3rd quarter valued at approximately $244,000. Finally, Creative Planning bought a new stake in Mesoblast in the 3rd quarter valued at $147,000. 1.43% of the stock is currently owned by hedge funds and other institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.